Skip to main content
letter
. 2022 Oct 26;6(11):e793. doi: 10.1097/HS9.0000000000000793

Figure 1.

Figure 1.

Percentage of ruxolitinib-treated patients with herpes zoster in the total study group (A) and stratified by MPN subtype (B). MPN = myeloproliferative neoplasm.